Relative potencies of several non-steroidal anti-inflammatory drugs against soya bean 15-lipoxygenase.
The 15-lipoxygenase from soya bean has been claimed to represent a rapid assay procedure for drugs and chemical agents that inhibit other lipoxygenase products (Kingston, 1981). Although the exact role of products derived from skin lipoxygenase enzymes is not well established, many of these products, e.g. leukotriene B4, have inflammatory characteristics that warrant further examination (Camp, 1982). We have therefore started to evaluate anti-inflammatory drugs in vitro for their ability to inhibit soya bean 15-lipoxygenase, before appraising their effects in vivo in animal and human skin.
D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors; D011720:Pyrazoles / Q000494:pharmacology; D013025:Glycine max
D000893:Anti-Inflammatory Agents; D005231:Fatty Acids, Unsaturated; D016859:Lipoxygenase Inhibitors; D011720:Pyrazoles; D015117:5,8,11,14-Eicosatetraynoic Acid; C026603:5,8,11-eicosatriynoic acid; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine